Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

John Mascarenhas; Mark L. Heaney; Vesna Najfeld; Elizabeth Hexner; Omar Abdel-Wahab; Raajit Rampal; Farhad Ravandi; Bruce Petersen; Gail Roboz; Eric Feldman; Nikolai Podoltsev; Dan Douer; Ross Levine; Martin Tallman; Ronald Hoffman

doi:10.1016/j.leukres.2012.08.013

Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

John Mascarenhas^*, Mark L. Heaney, Vesna Najfeld, Elizabeth Hexner, Omar Abdel-Wahab, Raajit Rampal, Farhad Ravandi, Bruce Petersen, Gail Roboz, Eric Feldman, Nikolai Podoltsev, Dan Douer, Ross Levine, Martin Tallman, Ronald Hoffman

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

Leukemic transformation (LT) of a myeloproliferative neoplasm (MPN) is associated with a dismal prognosis and no medical therapies have shown a survival improvement in patients with MPN in blast phase (MPN-BP). Effective therapies for the treatment of MPN-BP are a serious unmet need. Consensus response criteria do not exist for the treatment of patients with MPN-BP and this is necessary for the uniformed reporting of treatment response in clinical trials. We have identified relevant MPN and MPN-BP features in order to define treatment response categories that reflect hematological, clinical, pathological, cytogenetic and molecular changes after therapeutic intervention. We plan to validate these proposed response criteria within multi-centered clinical trials.

Original language	English (US)
Pages (from-to)	1500-1504
Number of pages	5
Journal	Leukemia Research
Volume	36
Issue number	12
DOIs	https://doi.org/10.1016/j.leukres.2012.08.013
State	Published - Dec 2012

Funding

Keywords

Acute myeloid leukemia
Blast phase
Clinical trial
Myeloproliferative neoplasm
Response criteria

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2012.08.013

Fingerprint

Dive into the research topics of 'Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium'. Together they form a unique fingerprint.

Cite this

Mascarenhas, J., Heaney, M. L., Najfeld, V., Hexner, E., Abdel-Wahab, O., Rampal, R., Ravandi, F., Petersen, B., Roboz, G., Feldman, E., Podoltsev, N., Douer, D., Levine, R., Tallman, M., & Hoffman, R. (2012). Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia Research, 36(12), 1500-1504. https://doi.org/10.1016/j.leukres.2012.08.013

@article{1ad64ce1a6304196823a93e03a7491bc,

title = "Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium",

abstract = "Leukemic transformation (LT) of a myeloproliferative neoplasm (MPN) is associated with a dismal prognosis and no medical therapies have shown a survival improvement in patients with MPN in blast phase (MPN-BP). Effective therapies for the treatment of MPN-BP are a serious unmet need. Consensus response criteria do not exist for the treatment of patients with MPN-BP and this is necessary for the uniformed reporting of treatment response in clinical trials. We have identified relevant MPN and MPN-BP features in order to define treatment response categories that reflect hematological, clinical, pathological, cytogenetic and molecular changes after therapeutic intervention. We plan to validate these proposed response criteria within multi-centered clinical trials.",

keywords = "Acute myeloid leukemia, Blast phase, Clinical trial, Myeloproliferative neoplasm, Response criteria",

author = "John Mascarenhas and Heaney, {Mark L.} and Vesna Najfeld and Elizabeth Hexner and Omar Abdel-Wahab and Raajit Rampal and Farhad Ravandi and Bruce Petersen and Gail Roboz and Eric Feldman and Nikolai Podoltsev and Dan Douer and Ross Levine and Martin Tallman and Ronald Hoffman",

year = "2012",

month = dec,

doi = "10.1016/j.leukres.2012.08.013",

language = "English (US)",

volume = "36",

pages = "1500--1504",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "12",

}

Mascarenhas, J, Heaney, ML, Najfeld, V, Hexner, E, Abdel-Wahab, O, Rampal, R, Ravandi, F, Petersen, B, Roboz, G, Feldman, E, Podoltsev, N, Douer, D, Levine, R, Tallman, M & Hoffman, R 2012, 'Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium', Leukemia Research, vol. 36, no. 12, pp. 1500-1504. https://doi.org/10.1016/j.leukres.2012.08.013

Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. / Mascarenhas, John; Heaney, Mark L.; Najfeld, Vesna et al.
In: Leukemia Research, Vol. 36, No. 12, 12.2012, p. 1500-1504.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP)

T2 - Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

AU - Mascarenhas, John

AU - Heaney, Mark L.

AU - Najfeld, Vesna

AU - Hexner, Elizabeth

AU - Abdel-Wahab, Omar

AU - Rampal, Raajit

AU - Ravandi, Farhad

AU - Petersen, Bruce

AU - Roboz, Gail

AU - Feldman, Eric

AU - Podoltsev, Nikolai

AU - Douer, Dan

AU - Levine, Ross

AU - Tallman, Martin

AU - Hoffman, Ronald

PY - 2012/12

Y1 - 2012/12

N2 - Leukemic transformation (LT) of a myeloproliferative neoplasm (MPN) is associated with a dismal prognosis and no medical therapies have shown a survival improvement in patients with MPN in blast phase (MPN-BP). Effective therapies for the treatment of MPN-BP are a serious unmet need. Consensus response criteria do not exist for the treatment of patients with MPN-BP and this is necessary for the uniformed reporting of treatment response in clinical trials. We have identified relevant MPN and MPN-BP features in order to define treatment response categories that reflect hematological, clinical, pathological, cytogenetic and molecular changes after therapeutic intervention. We plan to validate these proposed response criteria within multi-centered clinical trials.

AB - Leukemic transformation (LT) of a myeloproliferative neoplasm (MPN) is associated with a dismal prognosis and no medical therapies have shown a survival improvement in patients with MPN in blast phase (MPN-BP). Effective therapies for the treatment of MPN-BP are a serious unmet need. Consensus response criteria do not exist for the treatment of patients with MPN-BP and this is necessary for the uniformed reporting of treatment response in clinical trials. We have identified relevant MPN and MPN-BP features in order to define treatment response categories that reflect hematological, clinical, pathological, cytogenetic and molecular changes after therapeutic intervention. We plan to validate these proposed response criteria within multi-centered clinical trials.

KW - Acute myeloid leukemia

KW - Blast phase

KW - Clinical trial

KW - Myeloproliferative neoplasm

KW - Response criteria

UR - http://www.scopus.com/inward/record.url?scp=84868206008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868206008&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2012.08.013

DO - 10.1016/j.leukres.2012.08.013

M3 - Article

C2 - 22938832

AN - SCOPUS:84868206008

SN - 0145-2126

VL - 36

SP - 1500

EP - 1504

JO - Leukemia Research

JF - Leukemia Research

IS - 12

ER -

Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leukemia Research. 2012 Dec;36(12):1500-1504. doi: 10.1016/j.leukres.2012.08.013

Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this